コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ndividuals with diabetes among patients with diastolic heart failure.
2 sfunction and serum BNP levels in diagnosing diastolic heart failure.
3 ria set forth by the European Study Group on Diastolic Heart Failure.
4 ardiac cells, is a major clinical outcome of diastolic heart failure.
5 nderlying etiology to prevent progression to diastolic heart failure.
6 ntricular ejection fraction are said to have diastolic heart failure.
7 is magnified by the increasing prevalence of diastolic heart failure.
8 nfirm rather than establish the diagnosis of diastolic heart failure.
9 l dysfunction, increased blood pressure, and diastolic heart failure.
10 Third, among people with chronic systolic or diastolic heart failure, aldosterone is actually produce
11 who met the diagnostic criteria for definite diastolic heart failure; all the patients had signs and
12 atory patients with chronic mild to moderate diastolic heart failure and normal sinus rhythm receivin
13 h among titin alterations in systolic and in diastolic heart failure and ponder the evidence for titi
14 physiology of diastole, the pathogenesis of diastolic heart failure, and the diagnosis of diastolic
16 fted up and to the left in the patients with diastolic heart failure as compared with the controls.
18 t failure patients in the United States have diastolic heart failure (clinical heart failure with nor
21 ce of systolic and diastolic dyssynchrony in diastolic heart failure (DHF) patients and identify the
22 ic heart failure (SHF) and 399 patients with diastolic heart failure (DHF), 12% of whom were classifi
25 ugh our patients fulfilled the criteria for "diastolic heart failure," diastolic dysfunction was not
26 y hypertension in the absence of systolic or diastolic heart failure (e.g. prostaglandins, endothelin
28 amination cannot distinguish these patients (diastolic heart failure) from those with a depressed eje
32 ge BNP levels in patients with decompensated diastolic heart failure have been prognostic with respec
34 35+/-9%) or echocardiographically confirmed diastolic heart failure (HF) to assess telephonic DM ove
36 s been studied as a therapeutic strategy for diastolic heart failure, in which slow Ca(2+) reuptake i
37 rized by maladaptive myocardial hypertrophy, diastolic heart failure, increased myofilament Ca(2+) se
39 failure with preserved ejection fraction or diastolic heart failure is an increasingly prevalent dis
41 dysfunction, or to distinguish systolic from diastolic heart failure, is not supported by current dat
42 goxin was tested in an appreciable number of diastolic heart failure patients in the Digitalis Invest
44 ove CLinical Status And EXercise Capacity in Diastolic Heart Failure (RELAX) clinical trial (n=216) u
45 ove Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) trial, physiological var
47 t was significantly higher in the group with diastolic heart failure than in the control group (0.03+
48 e decline (tau) was longer in the group with diastolic heart failure than in the control group (59+/-
50 trates may improve symptoms in patients with diastolic heart failure, there are few data to indicate
51 diabetic myocardium may mediate fibrosis and diastolic heart failure, while preserving matrix homeost
52 ove Clinical Status and Exercise Capacity in Diastolic Heart Failure with Preserved Ejection Fraction
53 iative to treat more than 6000 patients with diastolic heart failure with spironolactone is in its fi
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。